Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34 + CD38 − cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34 + CD38 − ALDH int leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34 + CD38 − cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.
1. A method for identifying the presence of leukemic stem cells (LSC) in a sample from a subject suffering from acute myeloid leukemia (AML) comprising:
a) obtaining a biological sample from a subject;
b) isolating mononuclear cells from the sample of a);
c) allowing the cells of b) to take up a fluorescent substrate for the enzyme aldehyde dehydrogenase (ALDH) and labeling the cells with a conjugated anti-CD34 monoclonal antibody and a conjugated anti-CD38 monoclonal antibody and a conjugated anti-CD38 monoclonal antibody;
d) isolating CD34 + CD38 − mononuclear cells or population of cells from the cells of c) using flow cytometry;
e) measuring the ALDH activity of the cells or population of cells of d);
f) providing a reference non-AML sample;
g) comparing the levels of ALDH activity in the cells or population of cells from e) with the levels of ALDH activity in the cells or population of cells from the non-AML sample; and
h) identifying the cells or population of cells from g) that have an intermediate level of ALDH activity (CD34 + CD38 − ALDH int ) in the sample from the subject when compared to the level of ALDH activity of the CD34 + CD38 − in the non-AML sample as being LSC.
2. The method of claim 1 , wherein the type of AML is core binding factor AML.
3. The method of claim 1 , wherein the anti-CD34 monoclonal antibody is conjugated to phycoerythrin.
4. The method of claim 3 , wherein the anti-CD38 monoclonal antibody is conjugated to allophycocyanin.
5. A method for prediction of an increased risk of relapse after treatment in a subject suffering from acute myeloid leukemia (AML) comprising:
a) treating the subject diagnosed with AML with appropriate therapy;
b) obtaining a post-therapy biological sample from a subject;
c) allowing the cells of b) to take up a fluorescent substrate for the enzyme aldehyde dehydrogenase (ALDH) and labeling the cells with a conjugated anti-CD34 monoclonal antibody and a conjugated anti-CD38 monoclonal antibody and a conjugated anti-CD38 monoclonal antibody;
d) isolating CD34 + CD38 − mononuclear cells or population of cells from the cells of c) using flow cytometry;
e) measuring the ALDH activity of the cells or population of cells of d);
f) providing a reference non-AML sample;
g) comparing the levels of ALDH activity in the cells or population of cells from e) with the levels of ALDH activity in the cells or population of cells from the non-AML sample; and
h) identifying the cells or population of cells from g) that have an intermediate level of ALDH activity (CD34 + CD38 − ALDH int ) in the sample from the subject when compared to the level of ALDH activity of the CD34 + CD38 − in the non-AML sample as being LSC,
i) identifying the cells or population of cells from g) that have an intermediate level of ALDH activity (CD34 + CD38 − ALDH int ) in the sample from the subject when compared to the level of ALDH activity of the CD34 + CD38 − in the non-AML sample as being LSC; and
j) determining that the subject has an increased risk for relapse of AML, and identifying that subject for further treatment, when the presence of LSC are detected in the sample from the subject.
6. The method of claim 5 , wherein the type of AML is core binding factor AML.
7. The method of claim 5 , wherein the anti-CD34 monoclonal antibody is conjugated to phycoerythrin.
8. The method of claim 7 , wherein the anti-CD38 monoclonal antibody is conjugated to allophycocyanin.
9. A method for treatment of a subject suffering from acute myeloid leukemia (AML) comprising:
a) obtaining biological sample from a subject;
b) isolating mononuclear cells from the sample of a);
c) allowing the cells of b) to take up a fluorescent substrate for the enzyme aldehyde dehydrogenase (ALDH) and labeling the cells with a conjugated anti-CD34 monoclonal antibody and a conjugated anti-CD38 monoclonal antibody and a conjugated anti-CD38 monoclonal antibody;
d) isolating CD34 + CD38 − mononuclear cells or population of cells from the cells of c) using flow cytometry;
e) measuring the ALDH activity of the cells or population of cells of d);
f) providing a reference non-AML sample;
g) comparing the levels of ALDH activity in the cells or population of cells from e) with the levels of ALDH activity in the cells or population of cells from the non-AML sample; and
h) identifying the cells or population of cells from g) that have an intermediate level of ALDH activity (CD34 + CD38 − ALDH int ) in the sample from the subject when compared to the level of ALDH activity of the CD34 + CD38 − in the non-AML sample as being LSC;
i) treating the subject suffering from AML with appropriate therapy when LSC are identified in the sample from the subject;
j) repeating steps a) to h); and
k) determining that the subject has completed treatment for AML when the presence of LSC are not detected.
10. The method of claim 9 , wherein the method further comprises repeating steps a) to i) if the presence of LSC are detected.
11. The method of claim 9 , wherein the type of AML is core binding factor AML.
12. The method of claim 9 , wherein the anti-CD34 monoclonal antibody is conjugated to phycoerythrin.
13. The method of claim 12 , wherein the anti-CD38 monoclonal antibody is conjugated to allophycocyanin.